Key Product Details
Ser21-Thr288, with a C-terminal 6-His tag
N-terminal Sequence Analysis
Predicted Molecular Mass
Human T lymphocytes cultured for 72 hours with PHA were incubated for an additional 3 days in 96 well plates coated with 500 ng/mL
anti-CD3 and Recombinant Human TIM‑1/KIM‑1/HAVCR.
The ED50 for this effect is 0.2-0.8 µg/mL.
Optimal dilutions should be determined by each laboratory for each application.
Scientific Data Images for Recombinant Human TIM-1/KIM-1/HAVCR His-tag Protein, CF
Recombinant Human TIM-1/KIM-1/HAVCR His-tag Protein BioactivityRecombinant Human TIM-1/KIM-1/HAVCR (Catalog # 1750-TM) inhibits anti-CD3-induced proliferation of stimulated human T cells. Human T lymphocytes cultured for 72 hours with PHA were incubated for an additional 3 days in 96 well plates coated with 500 ng/mL anti-CD3 and Recombinant Human TIM‑1/KIM‑1/HAVCR. The ED50 for this effect is 0.2-0.8 µg/mL.
Formulation, Preparation and Storage
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
Reconstitute at 100 μg/mL in sterile PBS.
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
TIM-1 (T cell-immunoglobulin-mucin; also KIM-1 and HAVcr-1) is a 100 kDa, type I transmembrane glycoprotein member of the TIM family of immunoglobulin superfamily molecules (1-3). This gene family is involved in the regulation of Th1 and Th2-cell-mediated immunity. Human TIM-1 is synthesized as a 359 amino acid (aa) precursor that contains a 20 aa signal sequence, a 270 aa extracellular domain (ECD), a 21 aa transmembrane segment and a 48 aa cytoplasmic domain (4-6). The ECD contains one V-type Ig-like domain and a mucin region characterized by multiple PTTTTL motifs. The mucin region undergoes extensive O-linked glycosylation. The TIM-1 gene is highly polymorphic and undergoes alternate splicing (1). For instance, the presence of a six aa sequence (MTTTVP) at position # 137 of the mature molecule is associated with protection from atopy in people with a history of hepatitis A (7, 8). There are two cytoplasmic alternate splice forms of TIM-1. One is a long (359 aa) kidney form termed TIM-1b, and one is a short (334 aa) liver form termed TIM-1a. Both are identical through the first 323 aa of their precursors. TIM-1b contains a tyrosine phosphorylation motif that is not present in 1a (6). TIM-1 is also known to circulate as a soluble form. Constitutive cleavage by an undefined MMP (possibly ADAM33) releases an 85-90 kDa soluble molecule (6). The ECD of human TIM-1 is 50% and 43% aa identical to mouse and canine TIM-1 ECD, respectively. The only two reported ligands for TIM-1 are TIM-4 and the hepatitis A virus (4, 9). However, others are believed to exist, and based on the ligand for TIM-3, one may well be an S-type lectin (10). TIM-1 ligation induces T cell proliferation and promotes cytokine production (1, 10).
- Meyers, J.H. et al. (2005) Trends Mol. Med. 11:1471.
- Kuchroo, V.K. et al. (2003) Nat. Rev. Immunol. 3:454.
- Mariat, C. et al. (2005) Phil. Trans. R. Soc. B 360:1681.
- Feigelstock, D. et al. (1998) J. Virol. 72:6621.
- Ichimura, T. et al. (1998) J. Biol. Chem. 273:4135.
- Bailly, V. et al. (2002) J. Biol. Chem. 277:39739.
- Umetsu, D.T. et al. (2005) J. Pediatr. Gastroenterol. Nutr. 40:S43.
- Gao, P-S. et al. (2005) J. Allergy Clin. Immunol. 115:982.
- Zhu, C. et al. (2005) Nat. Immunol. 6:1245.
- Meyers, J.H. et al. (2005) Nat. Immunol. 6:455.
Product Specific Notices for Recombinant Human TIM-1/KIM-1/HAVCR His-tag Protein, CF
This product is covered by one or more of the following US Patents 7,300,652; 7,041,290; 6,664,385 and other US and foreign patents pending or issued.
For research use only